Doximity Inc (DOCS)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NYSE
Market Cap: $5.95B
Last updated: Nov 17, 2026 at 11:03 AM ET
Doximity Inc (DOCS) P/E Ratio & Valuation History
Doximity (DOCS) trades at 31.2x trailing earnings and 8.9x sales. Its P/E of 31.2x is below its 5-year median of 39.4x. Its forward P/E is 24.5x. The median P/E across 8 similar companies is 31.1x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 27.3% higher over the next year. Its free cash flow yield is 5.1%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 31.2x |
| Forward P/E | 24.5x |
| Price to sales | 8.9x |
| Price to book | 6.3x |
| EV/EBITDA | 25.2x |
| Price to FCF | 19.7x |
| EV/FCF | 19.0x |
| PEG | 0.6 |
| FCF yield | 5.1% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 31.2x | 39.4x | N/A |
| P/S | 8.9x | 15.6x | N/A |
| P/B | 6.3x | 7.2x | N/A |
Valuation History
Over the 5 year ends shown, its P/E ranged from 29.5x in 2025 to 77.1x in 2021. 2025 was the lowest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $44.28 | 29.5x | 13.2x | 8.5x |
| 2024 | $53.39 | 41.7x | 18.4x | 9.7x |
| 2023 | $28.04 | 31.2x | 11.7x | 6.0x |
| 2022 | $33.56 | 45.4x | 16.5x | 7.0x |
| 2021 | $50.13 | 77.1x | 23.7x | 11.3x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About DOCS
What is DOCS's forward P/E ratio?
Doximity has a forward P/E ratio of 24.5x.
Is DOCS stock overvalued?
GNG's valuation label for DOCS is Overvalued. Its P/E of 31.2x compares with a median of 31.1x across 8 similar companies.
What is DOCS's price to sales ratio?
Doximity has a price to sales ratio of 8.9x.
What is Doximity's average P/E ratio over 5 years?
Doximity's median P/E over the last 5 years is 39.4x, from 60 month-end values through Oct 2026.
What is DOCS's PEG ratio?
Doximity has a PEG ratio of 0.6.
DOCS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts